Limits...
Evaluation of Resettin® on serum hormone levels in sedentary males.

Anderson ML - J Int Soc Sports Nutr (2014)

Bottom Line: After 14 days, participants receiving 800 mg per day of Resettin® had significantly reduced baseline-subtracted serum DHT levels in comparison to the placebo control group.While after 14 days, participants receiving 1200 mg per day of Resettin® had significantly reduced baseline-subtracted serum DHT and E2 levels in comparison to the placebo control group.Moreover, participants receiving 1200 mg per day of Resettin® experienced a 38% increase in serum testosterone levels in comparison to the placebo control group, but the effect did not reach statistical significance.

View Article: PubMed Central - HTML - PubMed

Affiliation: R&D Department, Triarco Industries, Wayne, NJ, USA.

ABSTRACT

Background: Comparisons of hormones such as dihydrotestosterone (DHT), estradiol (E2), and testosterone indicate their impact on metabolism and body composition. While less is known regarding DHT and E2, testosterone is an androgenic metabolic hormone capable of positively regulating a variety of anabolic and androgenic processes in the body. Accordingly, it has been postulated that the age-related reduction in serum testosterone levels leads to reductions in lean muscle mass, bone mineral density, and other physical conditions that impair physical performance and decrease quality of life. Preliminary studies suggest that key ingredients found in Resettin®/MyTosterone™, a natural supplement containing the carotenoid astaxanthin from Haematococcus pluvialis and Saw Palmetto berry lipid extract from Serenoa repens, could positively impact testosterone levels. To investigate the clinical efficacy of Resettin®, the serum profiles of testosterone, E2 and DHT in healthy sedentary males before and after Resettin® treatment were evaluated in a randomized, placebo controlled clinical trial.

Method: Twenty healthy, sedentary men between the ages of 21 and 70 were randomized into either an 800 mg/day or 1200 mg/day Resettin®/MyTosterone™ treatment group or lecithin, which was used as the placebo. After a 14-day treatment period, there was a 14-day washout period. After the wash-out period, participants were crossed over within their respective group to either Resettin®/MyTosterone™ or the lecithin placebo for 14 days.

Results: After 14 days, participants receiving 800 mg per day of Resettin® had significantly reduced baseline-subtracted serum DHT levels in comparison to the placebo control group. While after 14 days, participants receiving 1200 mg per day of Resettin® had significantly reduced baseline-subtracted serum DHT and E2 levels in comparison to the placebo control group. Moreover, participants receiving 1200 mg per day of Resettin® experienced a 38% increase in serum testosterone levels in comparison to the placebo control group, but the effect did not reach statistical significance.

Conclusion: Although additional studies will be required to evaluate how Resettin® may promote proper testosterone regulation, these findings indicate that Resettin® can favorably influence serum hormone profiles in men.

No MeSH data available.


Related in: MedlinePlus

Baseline subtracted serum E2 levels in placebo- and Resettin®/MyTosterone™-treated participants. Shown are the serum E2 levels from participants after 3, 7 and 14 days of 800 mg/day placebo or Resettin®/MyTosterone™ (a), or 1200 mg/day placebo or Resettin®/MyTosterone™ (b) as determined by ELISA. Each experimental group had between 9 and 10 participants, and results are indicative of one trial. There was a statistically significant reduction in the average serum E2 concentration of the 1200 mg/day Resettin®/MyTosterone™ treatment group compared to that of the 1200 mg/day placebo control group (ANOVA-2; p < 0.05). Error bars denote standard deviation of the experimental mean. An asterisk (*) indicates statistical significance.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4151021&req=5

Figure 2: Baseline subtracted serum E2 levels in placebo- and Resettin®/MyTosterone™-treated participants. Shown are the serum E2 levels from participants after 3, 7 and 14 days of 800 mg/day placebo or Resettin®/MyTosterone™ (a), or 1200 mg/day placebo or Resettin®/MyTosterone™ (b) as determined by ELISA. Each experimental group had between 9 and 10 participants, and results are indicative of one trial. There was a statistically significant reduction in the average serum E2 concentration of the 1200 mg/day Resettin®/MyTosterone™ treatment group compared to that of the 1200 mg/day placebo control group (ANOVA-2; p < 0.05). Error bars denote standard deviation of the experimental mean. An asterisk (*) indicates statistical significance.

Mentions: Given that aromatase is capable of converting testosterone into E2, the serum concentrations of E2 were also evaluated by ELISA in all participants. Serum E2 levels did not significantly change relative to baseline levels. Further, there were no significant differences in the average serum E2 levels of the participants in the 800 mg/day and 1200 mg/day Resettin®/MyTosterone™ treatment groups as compared to the placebo control groups (Figure 2; ANOVA-RM; p > 0.05). Interestingly, when all serum E2 concentrations were adjusted by subtracting their baseline concentrations, results revealed a statistically significant reduction in the average serum E2 concentration of the 1200 mg/day Resettin®/MyTosterone™ treatment group compared to that of the 1200 mg/day placebo control group (Figure 2; ANOVA-2; p < 0.05).


Evaluation of Resettin® on serum hormone levels in sedentary males.

Anderson ML - J Int Soc Sports Nutr (2014)

Baseline subtracted serum E2 levels in placebo- and Resettin®/MyTosterone™-treated participants. Shown are the serum E2 levels from participants after 3, 7 and 14 days of 800 mg/day placebo or Resettin®/MyTosterone™ (a), or 1200 mg/day placebo or Resettin®/MyTosterone™ (b) as determined by ELISA. Each experimental group had between 9 and 10 participants, and results are indicative of one trial. There was a statistically significant reduction in the average serum E2 concentration of the 1200 mg/day Resettin®/MyTosterone™ treatment group compared to that of the 1200 mg/day placebo control group (ANOVA-2; p < 0.05). Error bars denote standard deviation of the experimental mean. An asterisk (*) indicates statistical significance.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4151021&req=5

Figure 2: Baseline subtracted serum E2 levels in placebo- and Resettin®/MyTosterone™-treated participants. Shown are the serum E2 levels from participants after 3, 7 and 14 days of 800 mg/day placebo or Resettin®/MyTosterone™ (a), or 1200 mg/day placebo or Resettin®/MyTosterone™ (b) as determined by ELISA. Each experimental group had between 9 and 10 participants, and results are indicative of one trial. There was a statistically significant reduction in the average serum E2 concentration of the 1200 mg/day Resettin®/MyTosterone™ treatment group compared to that of the 1200 mg/day placebo control group (ANOVA-2; p < 0.05). Error bars denote standard deviation of the experimental mean. An asterisk (*) indicates statistical significance.
Mentions: Given that aromatase is capable of converting testosterone into E2, the serum concentrations of E2 were also evaluated by ELISA in all participants. Serum E2 levels did not significantly change relative to baseline levels. Further, there were no significant differences in the average serum E2 levels of the participants in the 800 mg/day and 1200 mg/day Resettin®/MyTosterone™ treatment groups as compared to the placebo control groups (Figure 2; ANOVA-RM; p > 0.05). Interestingly, when all serum E2 concentrations were adjusted by subtracting their baseline concentrations, results revealed a statistically significant reduction in the average serum E2 concentration of the 1200 mg/day Resettin®/MyTosterone™ treatment group compared to that of the 1200 mg/day placebo control group (Figure 2; ANOVA-2; p < 0.05).

Bottom Line: After 14 days, participants receiving 800 mg per day of Resettin® had significantly reduced baseline-subtracted serum DHT levels in comparison to the placebo control group.While after 14 days, participants receiving 1200 mg per day of Resettin® had significantly reduced baseline-subtracted serum DHT and E2 levels in comparison to the placebo control group.Moreover, participants receiving 1200 mg per day of Resettin® experienced a 38% increase in serum testosterone levels in comparison to the placebo control group, but the effect did not reach statistical significance.

View Article: PubMed Central - HTML - PubMed

Affiliation: R&D Department, Triarco Industries, Wayne, NJ, USA.

ABSTRACT

Background: Comparisons of hormones such as dihydrotestosterone (DHT), estradiol (E2), and testosterone indicate their impact on metabolism and body composition. While less is known regarding DHT and E2, testosterone is an androgenic metabolic hormone capable of positively regulating a variety of anabolic and androgenic processes in the body. Accordingly, it has been postulated that the age-related reduction in serum testosterone levels leads to reductions in lean muscle mass, bone mineral density, and other physical conditions that impair physical performance and decrease quality of life. Preliminary studies suggest that key ingredients found in Resettin®/MyTosterone™, a natural supplement containing the carotenoid astaxanthin from Haematococcus pluvialis and Saw Palmetto berry lipid extract from Serenoa repens, could positively impact testosterone levels. To investigate the clinical efficacy of Resettin®, the serum profiles of testosterone, E2 and DHT in healthy sedentary males before and after Resettin® treatment were evaluated in a randomized, placebo controlled clinical trial.

Method: Twenty healthy, sedentary men between the ages of 21 and 70 were randomized into either an 800 mg/day or 1200 mg/day Resettin®/MyTosterone™ treatment group or lecithin, which was used as the placebo. After a 14-day treatment period, there was a 14-day washout period. After the wash-out period, participants were crossed over within their respective group to either Resettin®/MyTosterone™ or the lecithin placebo for 14 days.

Results: After 14 days, participants receiving 800 mg per day of Resettin® had significantly reduced baseline-subtracted serum DHT levels in comparison to the placebo control group. While after 14 days, participants receiving 1200 mg per day of Resettin® had significantly reduced baseline-subtracted serum DHT and E2 levels in comparison to the placebo control group. Moreover, participants receiving 1200 mg per day of Resettin® experienced a 38% increase in serum testosterone levels in comparison to the placebo control group, but the effect did not reach statistical significance.

Conclusion: Although additional studies will be required to evaluate how Resettin® may promote proper testosterone regulation, these findings indicate that Resettin® can favorably influence serum hormone profiles in men.

No MeSH data available.


Related in: MedlinePlus